These renewable, three-year, master agreements establish a framework for collaboration on a variety of initiatives across a range of AstraZeneca oncology products and research projects. Specific terms of the agreement were not disclosed.
These agreements broadly aim at producing better integration of preclinical and clinical research to more efficiently determine the effectiveness of innovative cancer treatments in helping patients. Scientists will combine resources and expertise in disease intervention and translational science to address key questions in the lab and later translate those findings to the clinic.
“Integrating ideas with industry earlier in the drug development process will enhance our ability to bring new treatments from the bench to the bedside more rapidly,” said Dr Robert Bast, vice president for translational research at Anderson. “To make the most rapid progress in the era of targeted therapies, we need new ways to organize our research and to collaborate with pharma for the benefit of our patients.”